Jessica is a Principal of Market Access advisory services practice with extensive experience partnering with life sciences organizations to drive strategic initiatives focused on healthcare transformation.

At Avalere Health, Jessica leads the annual dissection of the Medicare Physician Fee Schedule (MPFS), where she specializes in coverage, coding, regulatory, and economics—always with a strong focus on physician net cost recovery and enhancing the patient experience.

Throughout her career, Jessica has been deeply committed to diversity, equity, and inclusion (DEI). As a former member of the DEI council at Avalere Health and a mentor through a global program called Connections Mentoring at Bristol-Myers Squibb (BMS), she's had the privilege of supporting colleagues across seven different time zones, guiding their development and fostering a collaborative environment. She has been described as a compassionate, intelligent leader and mentor with a strong focus on collaboration and supporting the growth of others.

In previous roles, she played a pivotal part in transforming healthcare systems. At US Bioservices, she co-led the reimbursement department and oversaw the successful lift and shift to Inovalon's ScriptMed pharmacy operating system, streamlining operations across a national network of specialty pharmacies. Her efforts significantly enhanced both patient experiences and provider satisfaction. At BMS, she supported healthcare providers in gaining and maintaining access to the company's products, launching five major drugs, and breaking down financial barriers to ensure patients received essential medications.

She brings specialized knowledge as a Certified Professional Biller (CPB), with expertise in Medicare Part A, Part B, Part B durable medical equipment, and Part D drug reimbursement. She also has extensive experience managing physician buy-and-bill processes and pharmacy revenue cycle functions, particularly in therapeutic areas such as oncology, rheumatology, organ transplant, hepatitis C, IgG, and rare and orphan indications.

 She holds a Bachelor of Science in Biology, is a CPB through the AAPC, a Lean Six Sigma Green Belt and has prior experience as an EMT and Certified Pharmacy Technician (CPHT). Jessica's diverse background reflects her passion for advancing healthcare systems that benefit providers and patients.

Authored Content


Avalere’s new CY 2025–2026 Coding and Regulatory Calendar supports life sciences firms’ strategic planning for critical coding deadlines, timelines, and regulatory updates.

Join Avalere to learn about the new Medicare Prescription Payment Plan and what it means for Part D enrollees in 2025.

The MPPP introduces new considerations for Part D plans’ financial risk, operations, and enrollee engagement.

The OIG found oversight gaps in Medicare's RPM program, especially in billing accuracy and integrity, highlighting need for safeguards and provider education.

The MPPP will help improve Part D patient affordability, prompting manufacturers to reassess existing patient assistance programs and educational efforts.

The MPPP is a new payment option for Part D beneficiaries in 2025; patient groups will play a key role in supporting education and outreach on the program.

The Medicare Prescription Payment Plan will change how Medicare beneficiaries manage their Part D out-of-pocket costs, with implications across stakeholders.

SAD list placement will inform the channel that providers and patients use to access a therapy.

Avalere surveyed providers on the administrative and economic costs of white-bagging requirements on infusion centers.

Newly developed HCPCS codes will support increased access to oncology navigation services, which have been shown to improve patient outcomes.

The AMA’s upcoming CPT Editorial Panel meeting on coding and billing for remote monitoring will shape the future of digital health technology.

Manufacturers impacted by the Part B discarded drug refund policy should assess claims billing and adjudication patterns to inform mitigation strategy.

In CY 2024 rulemaking, CMS proposes operational clarification to the discarded drug refund policy finalized last year.

Starting July 1, providers must report the JZ modifier on all claims for single-use Part B drugs when applicable, including for products billed with an NOC code.

CMS recently convened stakeholders for a public HCPCS meeting to discuss billing, coding, and reimbursement of non-drugs and non-biological products.

Avalere’s expert presentations at the AXS23 Summit described IRA drug-pricing policies and the law’s impact on patient access and affordability.

Avalere survey finds 65% of providers experience challenges associated with billing, coding, and reimbursement for RPM.

The MPFS final rule implements the discarded drug refund requirement for certain single-use physician-administered drugs, presenting risks to manufacturers of these products.

Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.

As manufacturers prepare for discarded drug rebates to begin in 2023, an Avalere analysis identified 39 drugs at risk for rebates totaling $151 million.